Markers of the Male Urogenital Tract
AssigneeMount Sinai Hospital
InventorsKeith Jarvi, Eleftherios P. Diamandis, Andrei Drabovich
Life of this patent
Estimating the term…
Abstract
Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.
Claims16
A method for diagnosis of a urogenital condition in a subject comprising:
- (a) obtaining a sample from the subject;
- (b) subjecting the sample to a procedure to detect one or more urogenital marker or polynucleotide encoding the urogenital marker in the sample;
- (c) diagnosing the urogenital condition by comparing the amount or status of urogenital marker or polynucleotide encoding the urogenital marker to the amount or status of the urogenital marker or polynucleotide encoding the urogenital marker obtained from a control subject who does not suffer from the urogenital condition or a post-vasectomy subject,
- wherein the urogenital condition is non-obstructive azoospermia (NOA) or obstructive azoospermia (OA) and the urogenital marker is ECM1, TEX101 or LDHC.
8-10. (canceled)
A method for diagnosing NOA or OA, or distinguishing NOA and OA, in a subject comprising:
- (a) determining the amount of LDHC or polynucleotide encoding LDHC in a sample from the subject;
- (b) determining the amount of TEX101 or polynucleotide encoding TEX101 in the sample;
- (c) determining the amount of ECM1 or polynucleotide encoding ECM1 in the sample;
- (d) mathematically combining the results of step (a), step (b) and step (c) to provide a mathematical combination;
- and
- (e) comparing or correlating the mathematical combination to the presence of NOA or OA in the subject.
A diagnostic composition or kit comprising:
- (a) an agent that binds to a urogenital marker or hybridizes to a polynucleotide encoding such marker, wherein the urogenital markers are the markers of Table 1, 4, 6, 7, 8, 10, 11, 12 or 13;
- or
- (b) a set of markers comprising a plurality of polypeptides comprising or consisting of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more of the markers of Table 1, 2, 3, 4, 5, 6, 7, 8, 9 10, 11, 12 or 13;
- or
- (c) a set of markers comprising at least one marker selected from the group consisting of LDHC, ECM1 and TEX101;
- (d) an agent that binds to a urogenital marker or hybridizes to a polynucleotide encoding such marker, wherein the urogenital markers consist of at least one marker selected from the group consisting of LDHC, ECM1 and TEX101
(canceled)
16:
- A method for identifying potentially infertile males or evaluating male fertility following an event which may influence the subject's fertility comprising determining the status of urogenital markers or polynucleotides encoding the markers in a sample obtained from the subject wherein the markers are the markers of a diagnostic composition or kit of claim 13.
Dependencies are inferred from the claim text.